Littmann Karin, Petersen Eva R B, Pussinen Christel, Danielson Kristin, Djurisic Snezana, Eilertsen Heidi, Garabet Lamya, Greibe Eva, Lauritzen Trine, Olsen Dorte A, Othman Suher, Palimaru Irina, Westerlund Johanna
a Department of Clinical Chemistry, Karolinska University Hospital , Stockholm, Sweden.
b Department of Clinical Immunology and Biochemistry, Lillebaelt Hospital , Vejle, Denmark.
Scand J Clin Lab Invest. 2013;73(4):286-92. doi: 10.3109/00365513.2013.773064. Epub 2013 Mar 11.
Self-monitoring of blood glucose (SMBG) is important in diabetes management. Reliable and user-friendly instruments are essential. OneTouch Verio(®) is a new blood glucose concentration-measuring system designed to be used by patients with diabetes and healthcare professionals. The objective of the present study was to evaluate the analytical performance of the OneTouch Verio(®).
The OneTouch Verio(®) was evaluated by the Scandinavian evaluation of laboratory equipment for primary healthcare (SKUP) according to a protocol based on ISO 15197 and the American Diabetes Association (ADA) quality goals. Blood samples were collected and measured on the OneTouch Verio(®) by laboratory personnel and patients with diabetes (n = 91, randomized into groups receiving personal training or mail instructions for the OneTouch Verio(®) system). Results were compared to a validated routine method, imprecision and bias were calculated. User-friendliness was evaluated with a questionnaire.
Quality specifications for blood glucose concentration monitoring systems according to ISO 15197 were fulfilled. The mean coefficients of variation (CV%) of repeatability was 3.4% when tested by laboratory personnel and within the goal of imprecision suggested by ADA. Mean CV% of repeatability for patient self-monitoring was 5.0% and 5.1% in the training- and the mail group, respectively. Total error was 6.4-10.0%. The OneTouch Verio(®) showed no hematocrit interference or variation between strip lots.
The OneTouch Verio(®) displayed sufficient analytical quality and satisfactory user-friendliness. It is suitable for point-of-care testing of blood glucose concentration when handled by patients and healthcare professionals.
血糖自我监测(SMBG)在糖尿病管理中至关重要。可靠且用户友好的仪器必不可少。OneTouch Verio(®)是一种新型血糖浓度测量系统,专为糖尿病患者和医疗保健专业人员设计。本研究的目的是评估OneTouch Verio(®)的分析性能。
OneTouch Verio(®)由斯堪的纳维亚初级医疗保健实验室设备评估(SKUP)根据基于ISO 15197和美国糖尿病协会(ADA)质量目标的方案进行评估。实验室人员和糖尿病患者(n = 91,随机分为接受OneTouch Verio(®)系统个人培训或邮件指导的组)采集血样并使用OneTouch Verio(®)进行测量。将结果与经过验证的常规方法进行比较,计算不精密度和偏差。通过问卷调查评估用户友好性。
符合ISO 15197规定的血糖浓度监测系统质量规范。实验室人员测试时,重复性的平均变异系数(CV%)为3.4%,在ADA建议的不精密度目标范围内。患者自我监测的重复性平均CV%在培训组和邮件组分别为5.0%和5.1%。总误差为6.4 - 10.0%。OneTouch Verio(®)未显示血细胞比容干扰或试纸批次间的差异。
OneTouch Verio(®)表现出足够的分析质量和令人满意的用户友好性。当由患者和医疗保健专业人员操作时,它适用于血糖浓度的即时检测。